GlassScriptPhysician profile
Lee W Thompson
NPI 1063479905
$1,159.76
in general payments reported to CMS, 2019-2025
22 companies · $294 in 2025
The $294 reported for 2025 was less than what a typical Surgical Oncology provider received nationally (typical 2025 total: $288).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $65.07 · 2020: $124 · 2021: $148 · 2022: $166 · 2023: $37.51 · 2024: $324 · 2025: $294.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $656.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $655.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $279.04 | 2020-2025 | |
| Sirtex Medical INC | $169.91 | 2024 | Sir-Spheres Microspheres |
| Ethicon US, LLC | $82.70 | 2021-2025 | Echelon Flex |
| Tela Bio, INC. | $73.77 | 2023-2024 | Ovitex 2s, Ovitex Reinforced Bioscaffold With Permanent Polymer (Ovitex) |
| Trevena, INC. | $57.27 | 2022 | |
| Janssen Biotech, INC. | $51.00 | 2024-2025 | Talvey, Erleada, Balversa |
| Genzyme Corporation | $47.62 | 2025 | |
| Angiodynamics, INC. | $46.45 | 2019 | |
| Integra Lifesciences Corporation | $45.62 | 2022 | |
| Merck Sharp & Dohme LLC | $38.89 | 2022-2025 | Keytruda |
| Regeneron Healthcare Solutions, INC. | $37.70 | 2025 | Libtayo |
| Tersera Therapeutics LLC | $31.21 | 2025 | Zoladex |
| Biom'Up France Sas | $25.46 | 2020 | |
| Davol INC. | $24.08 | 2020 | |
| Baxter Healthcare | $21.69 | 2021 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stemline Therapeutics INC. | $20.50 | 2025 | Orserdu |
| Astrazeneca Pharmaceuticals LP | $19.58 | 2025 | Imfinzi |
| Covidien LP | $18.62 | 2019 | |
| Novartis Pharmaceuticals Corporation | $17.96 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $17.51 | 2023 | Gattex |
| Incyte Corporation | $16.75 | 2025 | Jakafi |
| Focal Therapeutics, INC. | $16.43 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lee Thompson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.